Medytox's No. 3 factory in Cheongju, North Chungcheong Province / Courtesy of Medytox By Park Jae-hyuk Medytox’s No. 3 factory in Cheongju, North Chungcheong Province, has received approval from the Ukrainian Center for Medical Certification and Prognostication for the production and export of the company’s hyaluronic acid (HA) filler, Neuramis.
The biopharmaceutical company said that the recent approval will increase the sales of Neuramis in Ukraine and its neighboring countries. Previously, Medytox exported Neuramis produced at its No. 1 plant, also located in Cheongju.
In response to the growing demand for filler in Ukraine and its neighboring countries, the company has decided to increase the production of Neuramis at its No. 3 plant. The size of the Ukrainian filler market is estimated to surpass $13 million.
With the latest approval, Medytox plans to export three types of Neuramis — Lidocaine, Deep Lidocaine and Volume Lidocaine — to Ukraine, which is regarded as a gateway for entering the Commonwealth of Independent States and East Europe. In 2017, Medytox started selling Neuramis in Ukraine, followed by the introduction of its botulinum toxin products in 2020. “Given that Ukraine is highly interested in K-beauty and has a great demand for cosmetic surgeries, its approval will help Neuramis raise its brand awareness and market share,” a Medytox official said.
“With the beginning of the No. 3 factory’s production of Neuramis for exports, we will make continuous efforts to export the product in other countries.” According to Medytox, Neuramis is safer than other HA fillers, as the company’s purification processing technology reduces the amount of residual butanediol diglycidyl ether (BDDE), so as to minimize side effects such as swelling and inflammatory responses.
The biopharmaceutical firm emphasized that Neuramis has maintained a leading status in the Korean filler market over the past 11 years. The product is also available in 35 countries, including Thailand and Brazil..
